PNC Financial Services Group
AKRO

PNC Financial Services Group’s Akero Therapeutics AKRO Stock Holding History

PNC Financial Services Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,776
Closed -$84.3K – 5158
2025
Q3 		$84.3K Sell
1,776
-176
-9% -$8.52K ﹤0.01% 2918
2025
Q2 		$104K Buy
1,952
+294
+18% +$13.4K ﹤0.01% 2685
2025
Q1 		$67.1K Buy
1,658
+390
+31% +$16.5K ﹤0.01% 2925
2024
Q4 		$35.3K Sell
1,268
-9
-0.7% -$273 ﹤0.01% 3281
2024
Q3 		$36.6K Buy
1,277
+10
+0.8% +$261 ﹤0.01% 3238
2024
Q2 		$29.7K Sell
1,267
-23
-2% -$492 ﹤0.01% 3292
2024
Q1 		$32.6K Buy
1,290
+1,229
+2,015% +$29.5K ﹤0.01% 3199
2023
Q4 		$1.42K Sell
61
-70
-53% -$1.38K ﹤0.01% 4246
2023
Q3 		$6.63K Buy
131
+88
+205% +$4.1K ﹤0.01% 3906
2023
Q2 		$2.01K Buy
43
+28
+187% +$1.28K ﹤0.01% 4380
2023
Q1 		$574 Hold
15
– – ﹤0.01% 4513
2022
Q4 		$822 Hold
15
– – ﹤0.01% 4445
2022
Q3 		$1K Buy
+15
New +$230 ﹤0.01% 4278

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PNC Financial Services Group's AKRO Position: Q4 2025 in Review

PNC Financial Services Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,776 shares — an estimated $84.3K sold.

PNC Financial Services Group first reported a position in AKRO in Q3 2022 and held it in 13 quarters. The position peaked at $104K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • PNC Financial Services Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 1,776 Akero Therapeutics shares in Q4 2025, an estimated $84.3K.
  • PNC Financial Services Group first reported a position in Akero Therapeutics in Q3 2022 and held it in 13 quarters.
  • PNC Financial Services Group's Akero Therapeutics position peaked at $104K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on PNC Financial Services Group's 13F filing for Q4 2025, filed 6 Feb 2026.